MELPHALAN News

MELPHALAN currently has 8 news articles, with 32 predicted indications.

This page combines the AI-predicted indications for MELPHALAN with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Evidence level: L5
Predicted indications (32):
- hereditary site-specific ovarian cancer syndrome (99.0%)
- familial ovarian cancer (99.0%)
- plasma cell myeloma (99.0%)
- maligant granulosa cell tumor of ovary (99.0%)
- malignant non-dysgerminomatous germ cell tumor of ovary (99.0%)
- malignant Sertoli-Leydig cell tumor of ovary (99.0%)
- borderline epithelial tumor of ovary (99.0%)
- ovarian clear cell adenocarcinoma (99.0%)
- malignant germ cell tumor of ovary (99.0%)
- ovarian mucinous adenocarcinoma (99.0%)
- yolk sac tumor (99.0%)
- ovarian adenocarcinoma (99.0%)
- immature ovarian teratoma (99.0%)
- ovarian endometrioid adenocarcinoma (99.0%)
- ovarian small cell carcinoma (99.0%)
- primary non-gestational choriocarcinoma of ovary (99.0%)
- ovarian cancer (99.0%)📰 ovarian cancer
- theca steroid-producing cell malignant tumor of ovary, not further specified (99.0%)
- hereditary breast ovarian cancer syndrome (99.0%)
- malignant dysgerminomatous germ cell tumor of ovary (99.0%)
- malignant sex cord stromal tumor of ovary (99.0%)
- ovarian carcinosarcoma (99.0%)
- gonadal germ cell tumor (99.8%)
- ovarian primitive germ cell tumor (99.8%)
- choriocarcinoma of ovary (99.7%)
- female breast carcinoma (99.7%)
- malignant non-epithelial tumor of ovary (99.5%)
- rectum mucinous adenocarcinoma (99.4%)
- colon mucinous adenocarcinoma (99.4%)
- gallbladder mucinous adenocarcinoma (99.3%)
- cervical mucinous adenocarcinoma (99.3%)
- endometrial mucinous adenocarcinoma (99.3%)